WEST Search History

DATE: Wednesday, July 30, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
L10	l8 same RGD	1	L10
L9	L8 and l5	0	L9
L8	l3 with (fusion adj protein)	618	L8
L7	l3 and L5	17	L7
L6	l3 and L5	17	L6
L5	RGD with conjugate$	95	L5
L4	l3 adj conjugte$ adj RGD	0	L4
L3	(interleukin-12 or il-12 or interleukin)	30733	L3
L2	L1 (w) RGD	2101995	L2
L1	(interleukin-12 or il-12 or interleukin) (w) conjugate$	2101415	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1646jxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:39:11 ON 30 JUL 2003

=> file caplus medline biosis embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:39:46 ON 30 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:39:46 ON 30 JUL 2003

FILE 'BIOSIS' ENTERED AT 10:39:46 ON 30 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 10:39:46 ON 30 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s interleukin (w) RGD (w) peptide
L1 0 INTERLEUKIN (W) RGD (W) PEPTIDE

=> s interleukin (w) RGD (w) peptide or Il (w) RGD (w) peptide
L2 0 INTERLEUKIN (W) RGD (W) PEPTIDE OR IL (W) RGD (W) PEPTIDE

=> s interleukin (s) (fusion (w) protein)
L3 2639 INTERLEUKIN (S) (FUSION (W) PROTEIN)

=> s (RGD-containing (w) peptide or RGD (w) peptide)
L4 4770 (RGD-CONTAINING (W) PEPTIDE OR RGD (W) PEPTIDE)

=> l3 and l4
L3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and l4
L5 2 L3 AND L4

=> d l5 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:319377 CAPLUS
DOCUMENT NUMBER: 138:333437
TITLE: Preparation of RGD-containing **fusion proteins** for targeting **interleukin** -12 to malignant endothelium
INVENTOR(S): Dickerson, Erin B.; Helfand, Stuart C.
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077818	A1	20030424	US 2001-801485	20010308

PRIORITY APPLN. INFO.: US 2001-801485 20010308

AB The present invention relates to bifunctional **fusion proteins** contg. a mammalian **interleukin**-12 operably linked to a arginine-glycine-aspartic acid (**RGD**)-**contg**. **peptide** that simultaneously target vascular and immune compartments within the tumor environment. Specifically, the fusion proteins of the present invention comprise a ligand for .alpha.v.beta.3, preferably a small peptide sequence comprising the sequence RGD, that specifically directs the fusion protein to angiogenic endothelial cells and .alpha.v.beta.3 pos. tumor cells. This vascular targeting peptide is coupled to interleukin-12 (IL-12), a cytokine with antiangiogenic activity mediated by induction of interferon-.gamma. and other antiangiogenic chemokines. Accordingly, using a fusion protein of the present invention, high concns. of IL-12 can be targeted to the tumor microenvironment thereby activating the tumoricidal responses of immune cells in situ and decreasing toxic side effects relating to the activity of IL-12 on nontumor tissues.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:658159 CAPLUS
DOCUMENT NUMBER: 137:200267
TITLE: Fusion proteins comprising immunoglobulin and target antigen with reduced T cell epitope and immunogenicity for therapeutic use
INVENTOR(S): Gillies, Stephen; Carr, Francis J.; Jones, Tim; Carter, Graham; Hamilton, Anita; Williams, Stephen; Hanlon, Marian; Watkins, John; Baker, Matthew; Way, Jeffrey C.
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066514	A2	20020829	WO 2002-EP1690	20020218
WO 2002066514	A3	20030213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2001-103955 A 20010219
EP 2001-108291 A 20010405

AB The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified mol. when exposed to a species in vivo. The invention relates, above all, to novel Ig fusion proteins which essentially consist of an Ig mol. or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biol. active non-Ig mol., preferably a polypeptide or protein or a biol. active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunol. target mol. which elicits biol. or pharmacol. efficacy. The mols. of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biol. activity as compared with the non-altered mols. The changes are made in regions of the mols. which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calcn. of T-cell epitope values for MHC Class II mol. binding sites in a peptide by computer-aided methods.

```
=> s cytokine (w) fusion (w) protein
L6          254 CYTOKINE (W) FUSION (W) PROTEIN

=> s l4 and l6
L7            2 L4 AND L6

=> d 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2002:658159  CAPLUS
DOCUMENT NUMBER:          137:200267
TITLE:                    Fusion proteins comprising immunoglobulin and target
                          antigen with reduced T cell epitope and
immunogenicity
                          for therapeutic use
INVENTOR(S):              Gillies, Stephen; Carr, Francis J.; Jones, Tim;
                          Carter, Graham; Hamilton, Anita; Williams, Stephen;
                          Hanlon, Marian; Watkins, John; Baker, Matthew; Way,
                          Jeffrey C.
PATENT ASSIGNEE(S):       Merck Patent G.m.b.H., Germany
SOURCE:                   PCT Int. Appl., 92 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
     WO 2002066514      A2    20020829      WO 2002-EP1690   20020218
     WO 2002066514      A3    20030213
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
```

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2001-103955 A 20010219
EP 2001-108291 A 20010405

AB The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified mol. when exposed to a species in vivo. The invention relates, above all, to novel Ig fusion proteins which essentially consist of an Ig mol. or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biol. active non-Ig mol., preferably a polypeptide or protein or a biol. active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunol. target mol. which elicits biol. or pharmacol. efficacy. The mols. of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biol. activity as compared with the non-altered mols. The changes are made in regions of the mols. which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calcn. of T-cell epitope values for MHC Class II mol. binding sites in a peptide by computer-aided methods.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:573686 CAPLUS
DOCUMENT NUMBER: 133:176175
TITLE: Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immunotherapies
INVENTOR(S): Lode, Holger N.; Reisfeld, Ralph A.; Cheresh; David A.; Gillies, Stephen D.
PATENT ASSIGNEE(S): The Scripps Research Institute, USA; Lexigen Pharmaceuticals Corporation
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047228	A1	20000817	WO 2000-US3483	20000211

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2360106	AA	20000817	CA 2000-2360106	20000211
EP 1156823	A1	20011128	EP 2000-910138	20000211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008161	A	20020528	BR 2000-8161	20000211
JP 2002536419	T2	20021029	JP 2000-598179	20000211
NO 2001003906	A	20011009	NO 2001-3906	20010810

PRIORITY APPLN. INFO.: US 1999-119721P P 19990212
WO 2000-US3483 W 20000211

AB The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amt. of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amt. of anti-tumor immunotherapeutic agent,
such as an anti-tumor antigen antibody/**cytokine fusion protein** having a cytokine and a recombinant Ig polypeptide chain sufficient to elicit a cytokine-specific biol. response.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.61	55.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

STN INTERNATIONAL LOGOFF AT 10:49:53 ON 30 JUL 2003